Average Insider

Where insiders trade, we follow

$MDGL
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-รŸ agonist, which is in Phase III clinical trials for the treatment of non-alcoholic steatohepatitis. The company also develops MGL-3745, a backup compound to resmetirom. It has research, development, and commercialization agreement with Hoffmann-La Roche. Madrigal Pharmaceuticals, Inc. is headquartered in West Conshohocken, Pennsylvania.
Healthcare
Sector
Biotechnology
Industry
William J. Sibold
CEO
528
Employees
$510.68
Current Price
$10.55B
Market Cap
52W Low$265.00
Current$510.6870.2% above low, 29.8% below high
52W High$615.00

Insider Activity Statistics

Aggregated buying and selling activity by time period
PeriodTypeInsidersTransactionsValueSharesBuy/Sell Ratio
1 weekBuys00---
Sells00--
2 weeksBuys00---
Sells00--
1 monthBuys00---
Sells00--
2 monthsBuys00--All Sells
Sells517$2,626,261.976,098
3 monthsBuys00--All Sells
Sells521$4,170,743.159,232
See activity going back 12 months โ€” create a free account

Insider Transactions

Recent purchases and sales by company insiders
DateInsiderTypeSharesPriceValueActions
Jan 26, 2026
Taub Rebecca
Director
Sale647$492.42$318,595.74View Details
264 more transactions available โ€” create a free account to see 12 months of history

Upcoming Earnings

Scheduled earnings reports
Apr 29, 2026
EPS
EstimatedN/A
ActualN/A
Revenue
EstimatedN/A
ActualN/A

Past Earnings

Historical earnings results
Feb 25, 2026
EPS
Estimated$0.01
ActualN/A
Revenue
EstimatedN/A
ActualN/A
Feb 19, 2026
EPS
Estimated$0.04
ActualN/A
Revenue
Estimated$312.74M
ActualN/A
3 more earnings records available โ€” create a free account to see 12 months of history
Version: v26.3.33